Why did pexelizumab fail to benefit acute myocardial infarction (STEMI) patients undergoing primary PCI? Insights into the role of inflammation and immunity and the complement inhibitor pexelizumab
Publication
, Journal Article
Theroux, P; Neumann, FJ; Hamm, CW; Mahaffey, KW; Hochman, JS; James, S; Montalescot, G; Stebbins, AL; Armstrong, PW; Granger, CB
Published in: EUROPEAN HEART JOURNAL
September 1, 2007
Duke Scholars
Published In
EUROPEAN HEART JOURNAL
ISSN
0195-668X
Publication Date
September 1, 2007
Volume
28
Start / End Page
384 / 385
Publisher
OXFORD UNIV PRESS
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Theroux, P., Neumann, F. J., Hamm, C. W., Mahaffey, K. W., Hochman, J. S., James, S., … Granger, C. B. (2007). Why did pexelizumab fail to benefit acute myocardial infarction (STEMI) patients undergoing primary PCI? Insights into the role of inflammation and immunity and the complement inhibitor pexelizumab. EUROPEAN HEART JOURNAL, 28, 384–385.
Theroux, P., F. J. Neumann, C. W. Hamm, K. W. Mahaffey, J. S. Hochman, S. James, G. Montalescot, A. L. Stebbins, P. W. Armstrong, and C. B. Granger. “Why did pexelizumab fail to benefit acute myocardial infarction (STEMI) patients undergoing primary PCI? Insights into the role of inflammation and immunity and the complement inhibitor pexelizumab.” EUROPEAN HEART JOURNAL 28 (September 1, 2007): 384–85.
Theroux P, Neumann FJ, Hamm CW, Mahaffey KW, Hochman JS, James S, et al. Why did pexelizumab fail to benefit acute myocardial infarction (STEMI) patients undergoing primary PCI? Insights into the role of inflammation and immunity and the complement inhibitor pexelizumab. EUROPEAN HEART JOURNAL. 2007 Sep 1;28:384–5.
Theroux, P., et al. “Why did pexelizumab fail to benefit acute myocardial infarction (STEMI) patients undergoing primary PCI? Insights into the role of inflammation and immunity and the complement inhibitor pexelizumab.” EUROPEAN HEART JOURNAL, vol. 28, OXFORD UNIV PRESS, Sept. 2007, pp. 384–85.
Theroux P, Neumann FJ, Hamm CW, Mahaffey KW, Hochman JS, James S, Montalescot G, Stebbins AL, Armstrong PW, Granger CB. Why did pexelizumab fail to benefit acute myocardial infarction (STEMI) patients undergoing primary PCI? Insights into the role of inflammation and immunity and the complement inhibitor pexelizumab. EUROPEAN HEART JOURNAL. OXFORD UNIV PRESS; 2007 Sep 1;28:384–385.
Published In
EUROPEAN HEART JOURNAL
ISSN
0195-668X
Publication Date
September 1, 2007
Volume
28
Start / End Page
384 / 385
Publisher
OXFORD UNIV PRESS
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology